TGF-β inhibitor, SB505124, resulted in a significant reduction of phosphorylated SMAD2 and inhibited the migration of fibroblasts stimulated by AF-MSC-hypoCM (Figure 4b). Here, TGFB1 is linked to atrial fibrillation.